Rezolute Announced Registered Direct Offering of 18.026M Shares Prices @ $3.80/Share
Benzinga · 05/02/2022 05:31
Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the pricing of an underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 12,921,055 shares of common stock at an offering price of $3.799 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Certain of the pre-funded warrants offered to investors are only exercisable upon receipt of stockholder approval of an increase in the authorized shares of Rezolute's common stock which Rezolute will first seek to obtain at an annual meeting of stockholders to be held by June 30, 2022, and the shares of common stock underlying such pre-funded warrants are not being registered under the Securities Act of 1933, as amended (the "Securities Act"). Concurrent with the underwritten registered direct offering, certain existing investors agreed to purchase pre-funded warrants to purchase up to 3,263,157 shares of common stock in a private placement at the same offering price as the offering price of the pre-funded warrants offered in the underwritten registered direct offering. Gross proceeds from the underwritten registered direct offering and the concurrent private placement before deducting underwriting discounts and commissions, placement agent fees and other offering expenses are expected to be approximately $130 million. The pre-funded warrants issued in the private placement and the shares of our common stock issuable upon exercise of such pre-funded warrants are not being registered under the Securities Act, but are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. All of the shares of common stock and pre-funded warrants sold in the underwritten registered direct offering and the concurrent private placement were sold by Rezolute. The closing of the offerings is expected to occur on or about May 4, 2022, subject to the satisfaction of customary closing conditions. The closing of the underwritten registered direct offering and the closing of the concurrent private placement are not contingent upon each other. Rezolute intends to use the net proceeds from these offerings to fund the continued activities for development of RZ358 for Congenital Hyperinsulinism and RZ402 for Diabetic Macular Edema and other pipeline development, working capital, and general corporate purposes. Jefferies is acting as the lead book-running manager, Cantor is acting as passive bookrunner, Canaccord Genuity and JMP Securities, A Citizens Company, are acting as co-lead managers and H.C. Wainwright & Co. is acting as co-manager for the underwritten registered direct offering. Jefferies is acting as lead placement agent, Cantor is acting as placement agent, and Canaccord Genuity, JMP Securities, A Citizens Company, and H.C. Wainwright & Co. are acting as co-placement agents for the concurrent private placement.